Orange Book product · Brand (NDA)
BONDLIDO
LIDOCAINE
At a glance
Sep 24, 2025
Approved
Brand (NDA)
Application
Not listed
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Sep 24, 2025
9 mo ago
Today
Exclusivity ends · NP
New product exclusivity (3 years)
Sep 24, 2028
in 2 yr 4 mo
Pharmaceutical detail
Active ingredient
LIDOCAINE
Strength
10%
Dosage form
SYSTEM
Route
TOPICAL
TE code
Not listed
Application
NDA 215029
Product number
001
Marketing status
RX
Reference listed drug (RLD)
Yes
Reference standard (RS)
Yes
Active-ingredient family
View full familyThis is a reference-listed drug (RLD) — the basis for generic (ANDA) applications. Other products sharing this ingredient are listed below.
- 2018ZTLIDOBrand (NDA)
NDA 207962 · SCILEX PHARMS
- 1999LIDODERMBrand (NDA)
NDA 020612 · TEIKOKU PHARMA USA
- 1996DENTIPATCHBrand (NDA)
NDA 020575 · NOVEN
- —XYLOCAINEBrand (NDA)
NDA 014394 · ASTRAZENECA
- —XYLOCAINEBrand (NDA)
NDA 008048 · ASTRAZENECA
- —XYLOCAINEBrand (NDA)
NDA 014127 · ASTRAZENECA
- —XYLOCAINEBrand (NDA)
NDA 013077 · ASTRAZENECA
- 2026LIDOCAINEGeneric (ANDA)
ANDA 207059 · USPHARMA
- 2025LIDOCAINEGeneric (ANDA)
ANDA 216484 · ALKEM LABS LTD
- 2025LIDOCAINEGeneric (ANDA)
ANDA 217221 · DIFGEN PHARMS
- 2024LIDOCAINEGeneric (ANDA)
ANDA 217117 · AUROBINDO PHARMA LTD
- 2021LIDOCAINEGeneric (ANDA)
ANDA 205882 · NAL PHARM
Marketing exclusivity (1)
- NPNew product exclusivity (3 years)
Sep 24, 2028
in 2 yr 4 mo
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
